Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)

Completed · Phase 2 · Has a placebo group

Conditions studied: Heart Failure, Heart Failure Preserved Ejection Fraction, Cardiovascular Diseases, Heart Diseases

In brief

The purpose of this study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower NT-proBNP in patients with chronic heart failure with preserved ejection fraction

Key facts

Study ID

NCT06215586

Run by

Cardurion Pharmaceuticals, Inc.

People needed

303

Starts

2024-02-13

Expected to finish

2025-09-02

Last updated by the study team

2025-11-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Is an adult male or female patient ≥ 18 years of age
• Has evidence in the medical history supporting a diagnosis of clinical HF syndrome, NYHA functional class II to III, with the duration of at least 6 months prior to the time of Screening. The HF syndrome is defined by documentation of 1 or more of the following:
• At least 1 of the typical symptoms due to HF such as dyspnea and/or fatigue limiting exercise capacity;
• At least 1 of the typical signs of HF such as peripheral edema, elevated jugular venous pressure, pulmonary crackles; or
• Hospitalization, emergency department visit, or outpatient visit for HF requiring intravenous (IV) or subcutaneous (SQ) diuresis within the past 12 months.
• Has ejection fraction (EF) >40% and left atrial enlargement by transthoracic echocardiogram (TTE) performed and interpreted locally at the time of Screening;
• Has NT-proBNP level ≥ 300 pg/mL at the time of Screening. Patients with atrial fibrillation or flutter at the time of Screening are required to have an NT proBNP level of ≥500 pg/mL at the time of Screening;
• Is on stable optimized doses of guideline-directed HF therapy, per Investigator's clinical judgment, for a minimum of 4 weeks prior to the time of Screening and during the Screening Period, with no planned changes after randomization; Has had no addition of new guideline-directed HF therapy within the 3 months prior to the time of Screening or during the Screening Period;

You may not qualify if…

• Has documented EF ≥ 60% by TTE within 6 months of the time of Screening or during the Screening Period;
• Has evidence of recent HF exacerbation defined by hospitalization or requirement for IV or SQ diuretics within 60 days of the time of Screening or during the Screening Period;
• Has a requirement for routine, scheduled outpatient IV infusions for HF (ie, inotropes, vasodilators, or diuretics) or routinely scheduled ultrafiltration;
• Has elective interventions (eg, percutaneous coronary intervention, device implantations, percutaneous structural heart disease interventions, cardiac and non-cardiac surgery) planned to occur during involvement in this study;
• Has acute coronary syndrome, stroke, transient ischemic attack, cardiac, carotid or other major cardiovascular surgery, or carotid angioplasty within 60 days of the time of Screening or during the Screening Period;
• Has had a prior or planned orthotopic heart transplantation;
• Has presence of or plan for mechanical circulatory support;
• Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Where it is running

• Cardurion Investigative Site — Little Rock, Arkansas, United States
• Cardurion Investigative Site — Orange, California, United States
• Cardurion Investigative Site — Torrance, California, United States
• Cardurion Investigative Site — Van Nuys, California, United States
• Cardurion Investigative Site — Jacksonville, Florida, United States
• Cardurion Investigative Site — Miami, Florida, United States
• Cardurion Investigative Site — Hazel Crest, Illinois, United States
• Cardurion Investigative Site — Peoria, Illinois, United States
• Cardurion Investigative Site — Alexandria, Louisiana, United States
• Cardurion Investigative Site — Covington, Louisiana, United States
• Cardurion Investigative Site — St Louis, Missouri, United States
• Cardurion Investigative Site — Buffalo, New York, United States
• Cardurion Investigative Site — New York, New York, United States
• Cardurion Investigative Site — Cleveland, Ohio, United States
• Cardurion Investigative Site — Oklahoma City, Oklahoma, United States
• Cardurion Investigative Site — Portland, Oregon, United States
• Cardurion Investigative Site — Rapid City, South Dakota, United States
• Cardurion Investigative Site — Nashville, Tennessee, United States
• Cardurion Investigative Site — Dallas, Texas, United States
• Cardurion Investigative Site — McKinney, Texas, United States
• Cardurion Investigative Site — Burlington, Vermont, United States
• Cardurion Investigative Site — Chermside, Australia
• Cardurion Investigative Site — Bruges, Belgium
• Cardurion Investigative Site — Sint-Niklaas, Belgium
• Cardurion Investigative Site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.